The application of adoptive cell therapy, which involves the ex vivo expansion of tumor-infiltrating CD8+ T lymphocytes from patients or CD8+ T lymphocytes from donors stimulated by specific tumor antigens to sufficient numbers, and then reinfusion into patients who have undergone lymphocyte chemotherapy, has largely compensated for the low immunogenicity of “cold tumors” and the immune blockade of the suppressive tumor microenvironment [20–22]. Here, CD8A is linked to neoplasm.